/ Print /

IN THE PIPELINE

Electroretinography: Out of the laboratory and into the clinicOCT has many benefits, yet falls short of reliably diagnosing and managing retinopathies and glaucoma. ERG remains the stalwart method for this application and this article highlights how technological advancements have enabled its introduction to the clinic.
Diagnosing early-stage AMD with a dark adaptation deviceA dark adaptometer (AdaptDx; MacuLogix Inc) can aid in the diagnosis of early-stage, or subclinical, age-related macular degeneration before visual loss occurs and even before structural changes are observed, and adds to the information obtained from retina cameras and OCT imaging.
Using automated capsulotomy in complicated cataract surgeriesAutomated capsulotomy is a new option that surgeons can choose for patients with opaque corneas, as well as when performing an open sky rhexis during the triple procedure and during surgery that requires the use of premium or multifocal lenses.
Drug shortage help on horizon
Drug shortage help on horizonWhile hospitals continue to face IV saline shortages after two hurricanes significantly damaged infrastructure in Puerto Rico, the situation should improve early this year.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
New treatment for advanced kidney cancer approved
New treatment for advanced kidney cancer approvedFDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
Ocularist videos attract eyeballsIn a world of mass production and high technology, an ocularist in Nottingham, United Kingdom, has inspired followers around the world with his high-touch approach to hand-crafting prosthetic eyes as portrayed in a couple of YouTube videos.
Pfizer won't launch its second Remicade biosimilar in U.S.
FDA okays short-acting follow-on insulin for diabetes
FDA okays short-acting follow-on insulin for diabetesFDA okays the first short-acting insulin approved as a “follow-on” product.
FDA okays new diabetes, asthma drugsFDA recently approved a new diabetes medication, as well as a drug to treat severe asthma.